Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and with a 100 per cent subsidiary dedicated to specialized services in protein interactions, will take part in the 9th Annual BIO Investor Forum organised by the Biotechnology Industry Organisation in San Francisco on October 5 and 6, 2010.
At the event, Hybrigenics’ management will present the major strategic breakthroughs achieved during the current financial year, and notably the definitive results of the Phase IIa clinical trials obtained with its flagship product, Inecalcitol, on October 6 at 8.30 am local time, ie 5.30 pm Paris time.
Hybrigenics’ participation in this prominent North American Forum for the biotechnology sector is in line with the Company’s commitment to strengthen its relations with its investors and to increase its visibility within the financial community.
